SKSimon Keely

Simon Keely

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Keely has a total of 559 co-authors. Here are the top co-authors by number of shared publications:

  • Nicholas J. Talley

    University of Newcastle, Australia

    31 shared publications
  • Nicholas J. Talley

    College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, Australia; Immune Health Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia; NHMRC Centre of Research Excellence in Transforming Gut Health, New Lambton Heights, Australia

    21 shared publications
  • Marjorie M. Walker

    Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia

    14 shared publications
  • Philip Michael Hansbro

    Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, Australia

    14 shared publications
  • Grace L. Burns

    College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia

    13 shared publications
  • Marjorie M. Walker

    College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia

    13 shared publications

Latest Publications

  • Open Access

    Assessing diet–microbiome associations with linear models: variability across human studies

    by Nicole M. Simm, Georgina M. Williams, Sophie Fowler, Katherine Barlow, Benazir Carter, Nicholas J. Talley, Simon Keely, Kerith Duncanson, Emily C. Hoedt

    1. Research investigating how relationships between diet and the gastrointestinal (GI) microbiome influence human health is highly topical. 1 Each year, thousands of papers report on diet–microbiom...

  • Open Access

    A microbiome meta-transcriptomics pipeline identifies a neutrophil elastase inhibitor that protects the colonic epithelial barrier

    by Bojan Stojkovic, Matthijs Bekkers, Jake P. Violi, Brett A. Neilan, Tan Hui Ying, Simon Keely, William A. Donald, Carlos Riveros, Gerard E. Kaiko

    Inflammatory Bowel Diseases (IBD) are lifelong conditions. Current therapeutic approaches target inflammatory signalling rather than improving barrier permeability or repair. The gut microbiome provides an exciting opportunity for novel drug discovery to leverage its role in healthy gut homeostasis. There is a clear need to identify bioactive molecules within the microbiota that could protect the intestinal barrier. Our group has developed a systematic pipeline using metatranscriptomic data to identify, produce, purify, and test microbial proteins in IBD, pinpointing multiple novel microbiota-derived proteins linked to disease activity. We identified a new microbiota protein (BMG-1), that specifically inhibits human neutrophil elastase, a pathogenic protease in IBD. This protease inhibition allows protection of the intestinal epithelial barrier from permeability and promotes epithelial healing. BMG-1 also reduces colon damage in a mouse model of colitis. Finally, we show that the native BMG-1 protein is not only present in human stool, but also significantly decreased in patients with high IBD activity. These findings demonstrate the gut microbiota can specifically regulate the balance of protease/anti-protease activity in the colon, and this represents a novel therapeutic strategy for IBD.


  • Open Access

    Unraveling anastomotic leak: biological mechanisms underlying intestinal healing after resection

    by Christie S. Catley, Emily C. Hoedt, Peter Pockney, Simon Keely, Kateleen E. Hedley

    Understanding intestinal healing following resection and anastomosis is a challenging topic due to the complexity of underlying mechanisms. Anastomotic healing follows the fundamental phases of normal wound repair; however, the intestinal anastomosis represents a unique biological environment in which factors such as the structure of the intestines, as well as the microbiome, may modify the healing process. Disruptions in any of the healing phases, such as the inflammatory, proliferative, and remodeling phase, may result in severe complications, characterized by the intraluminal contents leaking out into the extraluminal space, termed an anastomotic leak (AL). Despite decades of surgical advancements, we are still no closer to understanding the underlying AL etiology. It is clear that ALs are multifactorial in nature and contribute to by patient-, technical-, and biological-related factors; however, emerging evidence suggests that biological mechanisms may play a more significant role in AL pathology than originally believed. Evidence points to an interplay between epithelial healing, tissue oxygenation, and the resident microbiome in influencing mucosal healing at the anastomotic site. However, the precise contribution of these factors to failed anastomotic healing and AL etiology remains unclear. In this review, we examine the phases of healing, discuss the existing literature on biological factors affecting anastomotic healing, and describe the advancements made to improve AL rates by targeting the healing response.

  • Open Access

    Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence

    by Emily C. Hoedt, Grace L. Burns, Kateleen E. Hedley, Sophie Waller, Tamara Canento Sanchez, Olivia Chisolm, Helen MacCallum, Susan Richardson, Belinda Suthers, Elizabeth Pepper, et al.


  • Open Access

    Serological and faecal markers of irritable bowel syndrome: a systematic review and meta-analysis

    by Grace L. Burns, Freya Roberts, Jasmine A. Wark, Sophie Fowler, Michael P. Jones, Kerith Duncanson, Nicholas J. Talley, Simon Keely


  • Open Access

    A Scoping Review of Methods Used to Investigate Relationships between Dietary Intake and the Gastrointestinal Microbiome

    by Nicole M Simm, Georgina M Williams, Sophie Fowler, Katherine Barlow, Benazir Carter, Nicholas J Talley, Simon Keely, Kerith Duncanson, Emily C Hoedt

    The gastrointestinal (GI) microbiome is intrinsically linked to human health and disease, with dietary intake being a major modifiable variable contributing to microbial colonization and fermentation. Diet–microbiome studies are heterogeneous in the methods used to assess and record dietary intake, to sequence the microbiome data, and to analyze associations. To capture the extent of these inconsistencies, we performed a systematic scoping review to synthesize the information on methods used to assess and compare relationships between diet and the GI microbiome in human studies. Our search identified papers with metrics of both dietary intake and the GI microbiome (using either 16S rRNA or metagenomic shotgun sequencing) and specific diet–microbiome associative analysis. The databases searched were MEDLINE, EMBASE, CINAHL, Cochrane, and Google Scholar, and the search produced 22, 228 unique records after de-duplication. After full-text screening, 1,262 articles were selected for full extraction. A subset of 295 studies captured whole dietary intake and investigated associations with the GI microbiome. This subset assessed diet using 84 different food frequency questionnaires, 12 alternative surveys, and 4 types of diet recalls or diaries ranging from 1 to 14 days. Fifty-five percent (n = 163) of studies investigated habitual dietary intake, 35% (n = 101) investigated recent dietary intake, and 10% (n = 30) used methods to assess both. Eighty-one percent of studies employed 16S rRNA sequencing, with wide variation in extraction, sequencing, pre-processing, and annotation methods. Gaps in the reporting of the methods for each step of the sequencing and analysis process were evident, limiting future comparison of study outcomes. Microbiome-specific statistical methods were used in 11% of the subset—predominantly correlational methods that are not recommended for microbiome data. In conclusion, this review revealed extensive inconsistencies within the exploratory diet–microbiome studies, despite the existence of recommendations to assist researchers. Collaborative efforts to develop consensus in methods and reporting are needed to substantially progress the obtaining of high-quality evidence and meta-analysis in the diet–microbiome research field.


  • Antibiotics alter duodenal immune populations upon gluten exposure in mice: implications for non-coeliac gluten sensitivity

    by Jennifer C. Pryor, Emily C. Hoedt, Wai Sinn Soh, Sophie Fowler, Shandelle Caban, Kyra Minahan, Simonne Sherwin, Cheenie Nieva, Huw McCarthy, Jay Horvat, et al.

    A mouse model examined how microbial modulation affects immune responses to gluten. Antibiotic treatment followed by gluten reintroduction reduced duodenal Staphylococcus and altered microbial carbohydrate and lipid metabolism pathways in the fecal microbiome. Antibiotics and gluten treatment resulted in increased abundance and activation of duodenal eosinophils and elevated γδ T-cells in the duodenal epithelium. These findings highlight the role the microbiome plays in gluten-induced immune responses, providing insights into mechanisms behind non-celiac gluten sensitivity.

  • Altered Duodenal Mucosa‐Associated Microbiota and Immune Profiles in Functional Dyspepsia: A Study of Host‐Microbiome Homeostasis

    by Emily C. Hoedt, Grace L. Burns, Seungha Kang, Jessica Bruce, Mark Morrison, Simon Keely, Nicholas J. Talley

    Background: Recent work suggests an altered duodenal mucosa‐associated microbiota (d‐MAM) in patients with functional dyspepsia (FD) when compared to controls. This may reflect alterations in host‐microbiome homeostasis. Given the specific mucosal immune signatures identified in FD, we hypothesize that these signatures are associated with specific microbial changes. We aim to profile the d‐MAM to identify microbes associated with known changes in FD mucosal and peripheral immunity. Methods: Upper gastrointestinal biopsies were collected from 11 outpatient controls and 17 FD patients. Specific biopsies were collected for 16S rRNA sequencing, histology, and mucosal lamina propria mononuclear cell (LPMC) isolation. Where available, peripheral blood mononuclear cells (PBMC) were isolated. PBMC and LPMC populations were analyzed for T‐cell populations by flow cytometry. Key Results: Comparing the histological and immune measures between FD and controls revealed significant differences with decreased villi goblet cells and increased LPMC CD4 Central Memory, LPMC CD8, and PBMC CD4+ Central Memory Th17 in FD patients. Specific microbiome associations found that in controls, villi goblet cells positively correlated with Massilia and negatively with Exiguobacterium . Additionally, controls had a negative correlation between LPMC CD4 Central Memory and Veillonella . Notably, FD patients demonstrated a significant negative correlation between LPMC CD8 and Sulfophobococcus , and a positive correlation between PBMC CD4+ Central Memory Th17 and both Gemella and Fusobacterium . Conclusions and Inferences: Our findings contribute to a growing body of evidence, indicating FD patients exhibit distinct alterations in d‐MAM and immune profiles compared to controls. Furthermore, the immune‐microbiome associations within control populations were absent in FD patients, suggesting a loss of host‐microbiome homeostasis that may contribute to FD pathophysiology.


  • Therapies Targeting Mucosal Eosinophils in Eosinophilic Gut Diseases From Esophagus to Colon

    by Khaliun Batkhurel, Sharmila Prasad, Michael Potter, Jennifer H. Martin, Simon Keely, Nicholas J. Talley

    Eosinophilic gastrointestinal disorders (EGIDs) comprise eosinophilic oesophagitis (EoE) and non‐EoE EGIDs; these diseases may be increasing in prevalence and are likely underdiagnosed. Mortality is not increased in EoE but is in gastric and small intestinal EGIDs. A subtle increase in eosinophils has also been observed in other GI diseases including functional dyspepsia in the duodenum. Targeted drug therapy can markedly reduce eosinophil infiltration, although symptom response is more variable, suggesting that non–eosinophil pathways play a role in pathogenesis. Current standard therapies for EoE supported by randomized trials include proton pump inhibitors, corticosteroids (topical), diet restriction, and dupilumab, inhibiting IL‐4/IL‐13 signaling. In non‐EoE EGIDs where little randomized trial data exist, management is based on a combination of dietary elimination and corticosteroids or immunomodulators; mast cell stabilizers and antihistamine therapy may have a role. The role of combination therapies is unclear. Pharmacologic approaches in testing include new steroid preparations and delivery systems; dupilumab in eosinophilic gastritis; and anti‐IL‐13, anti‐IL‐5, anti‐IL‐2, and anti‐IL‐15 receptor targeting monoclonal antibodies.


  • Open Access

    Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel Diseases

    by Moniruzzaman, Ayesha Shah, Thomas Fairlie, Simon Keely, Grace L. Burns, Nicholas Talley, Gerald Holtmann

    Background and Objectives: Primary sclerosing cholangitis (PSC) is a chronic liver disease with aberrant immune dysregulation and bile duct fibrosis. It is often associated with inflammatory bowel disease (IBD), especially ulcerative colitis, raising questions about distinct immune activation in these conditions. Therefore, we aimed to systematically review and compare immune activation patterns in patients with PSC and IBD (without PSC), which may provide deeper insights into PSC pathophysiology. Methods: MEDLINE, Scopus, Cochrane Library, and Embase were searched until July 2024 for relevant studies reporting immune cell profiles, cytokine levels, and gene expression patterns in patients with PSC. Reference articles of patients with IBD were then added to compare the immune profile of patients with PSC (with or without IBD) and patients with IBD‐only. Results: Twenty‐three articles studying 638 PSC and 557 non‐PSC non‐IBD subjects were included. PSC patients showed various degrees of immune activation in the systemic circulation, biliary fluid, and liver tissue, most notably regarding integrin β7+ gut‐homing T cells, IL‐2, and IL‐10 compared to their respective controls. Compared with patients with IBD, patients with PSC had reduced Tregs in the systemic circulation. When comparing tissue‐based immune markers, PSC‐livers had increased Th17 cells, IL‐1β, and TNF‐α and reduced levels of B cells, IL‐2, and IL‐10 than the IBD‐mucosa. Conclusions: Patients with PSC and patients with IBD without PSC can be differentiated by a distinct immune activation pattern with upregulation of Th17 and downregulation of Treg functions in PSC while other immune parameters do not allow a differentiation of these conditions.